HZNP earnings call for the period ending March 31, 2020.
News & Analysis: Horizon Therapeutics
Investors were impressed with the company’s first-quarter financial results.
These companies scored recent drug approvals. It's worth looking into their stocks to see if they're a buy now.
2020 already looks promising for this profitable specialty pharma company despite global markets melting down.
HZNP earnings call for the period ending December 31, 2019.
Shares are up 4% following the announcement.
First FDA-approved medicine for thyroid eye disease.
Patients with this rare condition can now get relief for their symptoms.
An FDA panel’s vote lifted Horizon’s shares, but a steady rally will depend on the FDA’s approval decision.
With FDA approval deadlines approaching in 2020, these four drug developers could see substantial gains if they're successful.